AMBRISENTAN
Generic: AMBRISENTAN
Sigmapharm LaboratoriesManufacturer
ORALRoute
AMBRISENTANActive Substance
2019-04-10Original Approval
AMBRISENTAN is FDA application ANDA208354, sponsored by SIGMAPHARM LABS LLC. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
DYSPNOEA
9,196 reports
2
DEATH
7,206 reports
3
HEADACHE
5,768 reports
4
PNEUMONIA
4,388 reports
5
DIARRHOEA
4,075 reports
6
NAUSEA
3,435 reports
7
FATIGUE
3,354 reports
8
DIZZINESS
3,115 reports
9
MALAISE
2,652 reports
10
FLUID RETENTION
2,487 reports